COMPANY REGISTRATION NUMBER:
15466406
|
Unaudited Financial Statements |
|
Period from 5 February 2024 to 28 February 2025
|
Statement of comprehensive income |
2 |
|
|
|
Statement of financial position |
3 |
|
|
|
Notes to the financial statements |
4 |
|
|
Period from 5 February 2024 to 28 February 2025
The directors present their report and the unaudited financial statements of the company for the period ended
28 February 2025
.
Principal activities
The company did not trade during the period.
Directors
The directors who served the company during the period were as follows:
|
Mr. Aristeidis Vezenes |
(Appointed
5 February 2024) |
|
Mrs Sophia-Louise Ciccone |
(Appointed
5 February 2024) |
|
|
Small company provisions
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on
14 October 2025
and signed on behalf of the board by:
|
Mr. Aristeidis Vezenes |
Mrs Sophia-Louise Ciccone |
|
Director |
Director |
|
|
|
Statement of Comprehensive Income |
|
Period from 5 February 2024 to 28 February 2025
|
Period from |
|
5 Feb 24 to |
|
28 Feb 25 |
|
Note |
£ |
|
|
|
Administrative expenses |
(
15,719) |
|
-------- |
|
Operating loss |
(
15,719) |
|
|
|
-------- |
|
Loss before taxation |
(
15,719) |
|
|
|
Tax on loss |
– |
|
-------- |
|
Loss for the financial period and total comprehensive income |
(
15,719) |
|
-------- |
|
|
All the activities of the company are from continuing operations.
The company has no other recognised items of income and expenses other than the results for the period as set out above.
|
Statement of Financial Position |
|
28 February 2025
Current assets
|
Creditors: amounts falling due within one year |
5 |
(
19,939) |
|
-------- |
|
Net current liabilities |
(
15,619) |
|
-------- |
|
Total assets less current liabilities |
(
15,619) |
|
-------- |
|
Net liabilities |
(
15,619) |
|
-------- |
|
|
|
Capital and reserves
|
Called up share capital |
6 |
100 |
|
Profit and loss account |
(
15,719) |
|
-------- |
|
Shareholders deficit |
(
15,619) |
|
-------- |
|
|
|
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
For the period ending 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476
;
-
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements
.
These financial statements were approved by the
board of directors
and authorised for issue on
14 October 2025
, and are signed on behalf of the board by:
|
Mr. Aristeidis Vezenes |
Mrs Sophia-Louise Ciccone |
|
Director |
Director |
|
|
Company registration number:
15466406
|
Notes to the Financial Statements |
|
Period from 5 February 2024 to 28 February 2025
1.
General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is St Georges House 6th Floor, 15 Hanover Square, London, W1S 1HS, United Kingdom.
2.
Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Disclosure exemptions
The entity satisfies the criteria of being a qualifying entity as defined in FRS 102. Its financial statements are consolidated into the financial statements of (enter name of group financial statements) which can be obtained from (enter detail). As such, advantage has been taken of the following disclosure exemptions available under paragraph 1.12 of FRS 102: (a) No cash flow statement has been presented for the company.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4.
Debtors
|
28 Feb 25 |
|
£ |
|
Provision for credit notes |
4,320 |
|
------- |
|
|
5.
Creditors:
amounts falling due within one year
|
28 Feb 25 |
|
£ |
|
Trade creditors |
8,158 |
|
Accruals and deferred income |
1,800 |
|
Shareholder balance |
9,981
|
|
-------- |
|
19,939 |
|
-------- |
|
|
6.
Called up share capital
Issued, called up and fully paid
|
28 Feb 25 |
|
No. |
£ |
|
Ordinary shares of £ 1 each |
100 |
100 |
|
---- |
---- |
|
|
|